SKTO used to be a soft push-over. That's how a lot of us probably still think of it. Fortunately, there's now much more activity and liquidity in the trading. The volume numbers reflect this even at higher prices than afore.

SKTO is in play, though it has yet to take its rightful place in the top tier, if there is such a thing, of the mmj sector. Certainly, SKTO's small market cap is dwarfed by others with market caps in the hundreds of millions of dollars.

SKTO's promotion to the top tier can achieved by strong sales at the "over 400 collectives dispensaries," sales through PJ, and through the long awaited arrival of Dharmanol, to begin the introduction of  new and game-changing Berkeley Bio product lines. What Benz may have for us from CO is yet to be announced. And there are the wild cards of milestones, acquisitions, new appointments, joint ventures. 

There's much to look forward to. This is just the beginning, and we can be assured SKTO isn't about to lay down and quit.  lol